XTRA:FMEHealthcare
Fresenius Medical Care Refocuses Symvess Rights And Vascular Access Ambitions
Fresenius Medical Care (XTRA:FME) has amended its distribution agreement with Humacyte, Inc. regarding Symvess, an investigational acellular tissue engineered vessel.
The revision realigns ex U.S. rights to Symvess and reshapes how the two companies coordinate on access to this advanced vascular product outside the United States.
For you as an investor, this move sits at the intersection of medical technology and chronic kidney care, where XTRA:FME is a major global provider. Access to next...